80 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines
8-K
EX-99.1
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its
8-K
EX-99.1
VXRT
Vaxart Inc
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform
8-K
EX-99.1
fvk8fty
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
EX-99.1
ax7z4lyq60 gt8k
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
EX-99.1
b708tmra
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-99.1
sd7ykaqkl7k
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
xvy1vwpseiccnm6ev7e
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
winhe4g
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-99.1
df3l88m31r
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
oucxmlqimy
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
DEFA14A
jhx21w3z u3e
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
EX-99.1
5h2knif
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.2
u27urc6 j0r7
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
i14vtj2j4rj
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
EX-99.1
fwimquixo7k65
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
8-K
EX-99.1
rp1fl2k2cyo1wjysdfy
19 Dec 22
Vaxart Names Phillip Lee as Chief Financial Officer
5:25pm
8-K
EX-99.1
n62io33d68j
6 Dec 22
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
4:21pm